Standardized definitions of molecular response in chronic myeloid leukemiaCROSS, Ncp; WHITE, H. E; MÜLLER, M. C et al.Leukemia. 2012, Vol 26, Num 10, pp 2172-2175, issn 0887-6924, 4 p.Article

Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationSCORE, J; CALASANZ, M. J; WIEMELS, J et al.Leukemia. 2010, Vol 24, Num 10, pp 1742-1750, issn 0887-6924, 9 p.Article

Harmonization of molecular monitoring of CML therapy in EuropeMULLER, M. C; CROSS, Ncp; ERBEN, P et al.Leukemia. 2009, Vol 23, Num 11, pp 1957-1963, issn 0887-6924, 7 p.Article

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisisSOVERINI, S; SCORE, J; CERVANTES, F et al.Leukemia. 2011, Vol 25, Num 1, pp 178-181, issn 0887-6924, 4 p.Article

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutationMETZGEROTH, G; ERBEN, P; REITER, A et al.Leukemia. 2012, Vol 26, Num 1, pp 162-164, issn 0887-6924, 3 p.Article

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in > 80% of patients with TET2 and EZH2 being of high prognostic relevanceGROSSMANN, V; KOHLMANN, A; EDER, C et al.Leukemia. 2011, Vol 25, Num 5, pp 877-879, issn 0887-6924, 3 p.Article